This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

Monthly Archives: June 2018

//June

Canadian Consensus Position Statement for the Diagnosis and Management of MPS II

June 15, 2018 VANCOUVER, BC – Today, the Canadian MPS Society issued a national consensus statement that provides updated Canadian guidelines for the management of patients with MPS II. A consensus meeting was held in Toronto, Ontario, including a multidisciplinary group of experts in the management of patients with MPS II. The group reviewed available published guidelines [...]

Regenxbio receives FDA fast track designation for RGX-111 gene therapy for the treatment of MPS I

June 12, 2018 at 5:36 PM EDT - Novel, one-time, direct-to-CNS investigational treatment for MPS I designed to prevent the progression of cognitive deficits- Phase I clinical trial expected to enroll children and adults with MPS I- Expect to initiate patient recruitment and dosing in mid-2018 ROCKVILLE, Md., June 12, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), [...]

Clinical trial for genome editing treatment in MPS I and MPS II announced

"Patients with MPS I and MPS II have very few treatment options, and we are excited to expand access to our clinical trials to the U.K.," said Dr. Edward Conner, Chief Medical Officer at Sangamo. "We are pleased with the MHRA's rapid action on our CTA applications and to be working closely with them to advance [...]